Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $5.04, down 0.30% on the session, giving a market capitalisation of $402.9M. On trailing twelve-month figures it carries a trailing P/E of -2.39, a net margin of 0.0%. Its beta of 0.27 implies it has historically moved less than the broad market.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Atea Pharmaceuticals, Inc. is most often compared with the following Healthcare names: